We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PD-1/PD-L1免疫抑制剂在HBV感染相关肝细胞癌中的有效性及安全性分析.
- Authors
程然; 徐小元
- Abstract
Combined immunotherapy for hepatocellular carcinoma( HCC) based on immune checkpoint inhibitors( ICIs), especially programmed death receptor-1( PD-1) /programmed death-ligand 1( PD-L1) inhibitors, has achieved a remarkable clinical effect in clinical research and practice. Hepatitis B virus( HBV) infection is considered a major risk factor in the process of HCC. Studies are being conducted to investigate the efficacy and safety of PD-1/PD-L1 ICIs used alone or in combination in the treatment of patients with HBV-associated HCC, and some studies have shown that the patients with HBV-associated HCC receiving PD-1/PD-L1 inhibitors have achieved a similar treatment outcome to those without HBV infection; however, no consensus has been reached on the safety issues related to HBV activation. This article reviews the clinical trials of PD-1/PD-L1 blockade immunotherapy for HCC, so as to clarify the safety and efficacy of this new treatment regimen in the particular circumstances of HBV infection.
- Publication
Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi, 2022, Vol 38, Issue 9, p2160
- ISSN
1001-5256
- Publication type
Article
- DOI
10.3969/j.issn.1001-5256.2022.09.041